Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval [Yahoo! Finance]
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: Yahoo! Finance
in now . On February 17, CEO Andrew Robbins reiterated that Cogent Biosciences Inc. (NASDAQ:COGT) has started 2026 with tremendous momentum backed by multiple value-creating regulatory catalysts. Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval ldutko/Shutterstock.com In January, the US Food and Drug Administration accepted the company's PEAK New Drug Application for bezuclastinib in patients with Gastrointestinal Stromal Tumors (GIST). Consequently, the company submitted to the FDA, having already secured Breakthrough Therapy Designation. The slate of positive regulatory milestones comes on the candidate drug showing clear clinical benefit across all symptom domains. Cogent Biosciences is on the cusp of launching bezuclastinib in the second half of 2026, awaiting FDA approval. Six Abstracts from the SUMMIT trial of bezuclastinib in patients with Non-Advanced Systemic Mastocytosis (NonAdvSM) have already been accepted for presentation at the
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- A Look At Cogent Biosciences (COGT) Valuation After Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
- Bezuclastinib SUMMIT Data Reframe Cogent Biosciences Mastocytosis Opportunity [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual MeetingGlobeNewswire
- Analyst Bullish on Cogent (COGT) Amid Expected Drug Approval [Yahoo! Finance]Yahoo! Finance
COGT
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form S-8
- 2/17/26 - Form SCHEDULE
- COGT's page on the SEC website